Health Care • Biotechnology: Pharmaceutical Preparations
$2.36 ▼ -0.05
(-2.08%)
MKT CAP: $166.9M • VOL: 1.13M
52W L $1 52W H $8
ROARABLE / RQD
D- • 38/100
PIOTROSKI
3 / 9
PEPG // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$93.6M | -$97.7M | -$84.8M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$89.7M | -$90.0M | -$78.6M |
| EBITDA (Normalized) | -$93.4M | -$97.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$81.6M | -$82.4M | -$69.0M |
| Capital Expenditures (CapEx) | $264.0K | $497.0K | — |
| Free Cash Flow (FCF) | -$81.9M | -$82.9M | -$69.0M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $60.5M | $49.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $147.4M | $118.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PEPG.